New Delhi, Aug 13 (PTI) The first nasal vaccine against COVID-19, developed by Bharat Biotech, has received regulator's nod for conducting phase 2 and 3 clinical trials, the Department of Biotechnology said on Friday.

Phase 1 clinical trial has been completed in age groups ranging from 18 to 60 years, it said.

Also Read | Twitter India MD Manish Maheshwari Moves to US With New Role Amid Political Storm Over Blocking of Congress and Its Leaders' Accounts.

"Bharat Biotech's intranasal vaccine is the first nasal vaccine that has received the regulatory approval for Phase 2/3 trials," the DBT said.

This is the first of its kind COVID-19 jab to undergo human clinical trials in India.

Also Read | Independence Day 2021: Delhi’s IGI Airport to Have Restrictions in Place For August 15.

BBV154 is an intranasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vectored vaccine.

Bharat Biotech has in-licensed technology from Washington University in St Louis, US.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)